Yuekang Pharmaceuticals: Subsidiary YKYY018 Nebulized Inhalation Drug Approved by FDA for Conducting Clinical Trials on Respiratory Syncytial Virus Indications in Humans.

Yuekang Pharmaceutical announced on March 24th that its wholly-owned subsidiary, Yuekang Science and Innovation, has recently received approval from the US FDA to conduct clinical trials for its YKYY018 nebulized inhalation solution for the treatment and prevention of human parainfluenza virus infections. This product is a membrane fusion inhibitor independently developed by the company using AI technology, and has obtained global exclusive rights. It has previously been approved for conducting clinical trials related to respiratory syncytial virus. This new indication signifies the expansion of the drug's use in the prevention and treatment of multiple respiratory viruses. Preclinical studies have shown significant inhibitory effects on human parainfluenza virus and respiratory syncytial virus, with good safety. The company advises that drug development involves uncertainty and risks in subsequent developments.